Boston Scientific Co. (NYSE:BSX) Shares Sold by Gateway Investment Advisers LLC

Gateway Investment Advisers LLC decreased its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 600,025 shares of the medical equipment provider's stock after selling 5,381 shares during the quarter. Gateway Investment Advisers LLC's holdings in Boston Scientific were worth $53,594,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of BSX. Global Wealth Strategies & Associates boosted its position in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 250 shares in the last quarter. West Oak Capital LLC acquired a new position in shares of Boston Scientific during the 4th quarter worth $29,000. Dunhill Financial LLC boosted its position in shares of Boston Scientific by 86.4% in the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after buying an additional 152 shares in the last quarter. Values First Advisors Inc. acquired a new stake in Boston Scientific in the 3rd quarter valued at about $28,000. Finally, E Fund Management Hong Kong Co. Ltd. purchased a new position in Boston Scientific during the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares of the company's stock, valued at $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the firm's stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now owns 39,398 shares in the company, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock valued at $2,702,261 over the last 90 days. Corporate insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Royal Bank of Canada upped their price target on shares of Boston Scientific from $95.00 to $98.00 and gave the company an "outperform" rating in a report on Thursday, October 24th. JPMorgan Chase & Co. increased their target price on Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a report on Monday, December 16th. TD Cowen boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Thursday, December 12th. Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Finally, Sanford C. Bernstein lifted their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Three investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $97.26.

Boston Scientific Trading Up 1.3 %

Shares of BSX traded up $1.26 during trading hours on Thursday, hitting $98.15. The stock had a trading volume of 5,020,057 shares, compared to its average volume of 5,327,683. The company's fifty day simple moving average is $90.57 and its 200 day simple moving average is $84.23. Boston Scientific Co. has a 12-month low of $59.85 and a 12-month high of $98.31. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The firm has a market cap of $144.65 billion, a P/E ratio of 81.11, a P/E/G ratio of 2.48 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. The business had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company's revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.50 EPS. Equities research analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.